NAGE Q2 2020 Earnings — Niagen Bioscience Inc Revenue & Financial Results | Market Cap Arena

NAGENiagen Bioscience Inc

$393M

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$15M+37.7% YoY

Gross Profit

$9M59.4% margin

Operating Income

-$4M-24.1% margin

Net Income

-$4M-24.3% margin

EPS (Diluted)

$-0.06

QoQ Revenue Growth

+6.6%

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$2M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$42M

Total Liabilities

$20M

Stockholders' Equity

$22M

Cash & Equivalents

$19M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$15M	$11M	+37.7%
Gross Profit	$9M	$6M	+45.3%
Operating Income	-$4M	-$7M	+48.6%
Net Income	-$4M	-$8M	+52.1%